The Zur Rose Group in 2022 in facts and figures.
E-script
National roll-out of e-prescriptions started in Germany
59.2m
EBITDA improvement (adjusted) in CHF
139m
Funds raised for refinancing and general corporate purposes in CHF
1/3
Percentage of women on the Board of Directors – target reached a year ahead of schedule
New logistics
Automation level increased in Heerlen to 70 per cent and capacity more than doubled to 27 million packages per year
Structure
medpex brand successfully integrated at the Heerlen location and the Eurapon brand discontinued
Sustainability
Second year of reporting focused on setting targets, optimised governance structure, carbon footprint, diversity and inclusion
+9.5%
Significant growth in Switzerland